Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer.,Cancer Genomics & Proteomics

当前位置： X-MOL 学术 › Cancer Genom. Proteom. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer.
Cancer Genomics & Proteomics ( IF 2.5 ) Pub Date : 2021-2-21 , DOI: 10.21873/cgp.20249
Aliki Ntzifa ₁ , Areti Strati ₁ , Georgia-Angeliki Koliou ₂ , Flora Zagouri ₃ , Dimitrios Pectasides ₄ , George Pentheroudakis _{5,

6} , Christos Christodoulou ₇ , Helen Gogas ₈ , Christina Magkou ₉ , Constantina Petraki ₁₀ , Paris Kosmidis ₁₁ , Gerasimos Aravantinos ₁₂ , Vassiliki Kotoula _{13,

14} , George Fountzilas _{14,

15,

16} , Evi Lianidou ₁₇

Affiliation

Analysis of Circulating Tumor Cells Laboratory, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.
Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece.
Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece.
Department of Medical Oncology, Medical School, University of Ioannina, Ioannina, Greece.
Society for Study of Clonal Heterogeneity of Neoplasia (EMEKEN), Ioannina, Greece.
Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Pathology Department, Evangelismos Hospital, Athens, Greece.
Department of Pathology, Metropolitan Hospital, Piraeus, Greece.
Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aristotle University of Thessaloniki, Thessaloniki, Greece.
German Oncology Center, Limassol, Cyprus.
Analysis of Circulating Tumor Cells Laboratory, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece;

Effective targeted therapies for triple-negative breast cancer (TNBC) are limited. In a subset of TNBC, androgen receptor (AR) plays an important role, while the human proviral integration site for Moloney murine leukemia virus-1 (PIM1) overexpression is also implicated. PIM1 kinases phosphorylate AR, thus regulating its transcriptional activity, regardless of the presence or not of androgens. We evaluated the expression of AR and PIM1 and their prognostic significance in TNBC.

中文翻译：

三阴性乳腺癌患者肿瘤组织中的雄激素受体和 PIM1 表达。

三阴性乳腺癌 (TNBC) 的有效靶向治疗是有限的。在 TNBC 的一个子集中，雄激素受体 (AR) 起着重要作用，而莫洛尼鼠白血病病毒-1 (PIM1) 过度表达的人类原病毒整合位点也有牵连。无论是否存在雄激素，PIM1 激酶都会磷酸化 AR，从而调节其转录活性。我们评估了 AR 和 PIM1 的表达及其在 TNBC 中的预后意义。

更新日期：2021-02-22

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>